

**ONDINE BIOMEDICAL INC.**  
("Ondine Biomedical", "Ondine", or the "Company")

**Director Holdings**

**Ondine Biomedical Inc.** (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, confirms that following admission of the second tranche of new common shares at 8.00 a.m. on 22 November 2024 in relation to the Fundraising, the directors' interests in the Company are as follows:

| Director                          | Total number of common shares | % of issued share capital |
|-----------------------------------|-------------------------------|---------------------------|
| <b>Carolyn Cross</b> <sup>1</sup> | 155,864,029                   | 38.58%                    |
| <b>Nicolas Loebel</b>             | 3,513,991                     | 0.87%                     |
| <b>Junaid Bajwa</b>               | 1,193,697                     | 0.30%                     |
| <b>Jean Duval</b>                 | 1,163,529                     | 0.29%                     |
| <b>Michael Farrar</b>             | 484,806                       | 0.12%                     |
| <b>Jean Charest</b>               | 353,356                       | 0.09%                     |
| <b>Margaret Shaw</b>              | 213,853                       | 0.05%                     |

<sup>1</sup> Existing beneficial holding includes 118,091,377 shares held by Carolyn Cross, including via holdings in 100% owned companies, and 37,772,652 shares held by Robert Cross, husband of Carolyn Cross.

-Ends-

**Enquiries:**

**Ondine Biomedical Inc.**

Angelika Vance, Corporate Communications

+001 604 838 2702

**Singer Capital Markets (Nominated Adviser & Joint Broker)**

Phil Davies, Sam Butcher

+44 (0)20 7496 3000

**RBC Capital Markets (Joint Broker)**

Rupert Walford, Kathryn Deegan

+44 (0)20 7653 4000

**Vane Percy & Roberts (Media Contact)**

Simon Vane Percy, Amanda Bernard

+44 (0)77 1000 5910

**About Ondine Biomedical Inc.**

Ondine Biomedical Inc. is a Canadian life sciences company and leader innovating light-activated antimicrobial therapies (also known as 'photodisinfection'). In addition to Steriwave, Ondine has a pipeline of products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFLFSSLTLLFIS